QUTENZA
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Neuralgia, Postherpetic
Conditions
Neuralgia, Postherpetic
Trial Timeline
Oct 28, 2010 → Sep 26, 2013
NCT ID
NCT01252160About QUTENZA
QUTENZA is a approved stage product being developed by Astellas Pharma for Neuralgia, Postherpetic. The current trial status is completed. This product is registered under clinical trial identifier NCT01252160. Target conditions include Neuralgia, Postherpetic.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02171182 | Pre-clinical | Completed |
| NCT01478607 | Phase 3 | Completed |
| NCT01252160 | Approved | Completed |
Competing Products
20 competing products in Neuralgia, Postherpetic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Placebo + DS-5565 | Daiichi Sankyo | Pre-clinical | 23 |
| ASP8477 + Placebo | Astellas Pharma | Phase 2 | 52 |
| E2007 (perampanel) + Placebo | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2/3 | 65 |
| KHK6188 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Galcanezumab | Eli Lilly | Approved | 85 |
| Placebo + Pregabalin SR tablet 165mg/day + Pregabalin SR tablet 330mg/day + Pregabalin SR tablet 660mg/day | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| ABT-894 + ABT-894 + ABT-894 + placebo + Duloxetine | AbbVie | Phase 2 | 52 |
| MK-8291 + Placebo | Merck | Phase 1 | 33 |
| Etoricoxib + Placebo | Merck | Approved | 85 |
| Cetuximab + Placebo | Merck | Phase 2 | 52 |
| ADL5747 + Placebo + Pregabalin | Merck | Phase 2 | 52 |
| MK0759 | Merck | Phase 2 | 52 |
| MK0686 | Merck | Phase 2 | 52 |
| Comparator: pregabalin + Comparator: Placebo (unspecified) | Merck | Phase 1 | 33 |
| EMA401 + Placebo | Novartis | Phase 2 | 52 |
| pregabalin | Pfizer | Approved | 84 |
| Lyrica (pregabalin) + Placebo | Pfizer | Approved | 84 |
| 2-weeks placebo then gabapentin + 1-week placebo then gabapentin | Pfizer | Pre-clinical | 22 |